-
1
-
-
77951440698
-
-
World Health Organization Accessed June 20, 2013
-
World Health Organization. WHO fact sheet 164-hepatitis C. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed June 20, 2013.
-
WHO Fact Sheet 164-hepatitis C
-
-
-
2
-
-
79960453276
-
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
-
European Association for the Study of the Liver
-
European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
-
(2011)
J Hepatol
, vol.55
, pp. 245-264
-
-
-
3
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
-
M.G. Ghany, D.R. Nelson, and D.B. Strader et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
-
4
-
-
84862850805
-
APASL consensus statements and management algorithms for hepatitis C infection
-
M. Omata, T. Kanda, and M.-L. Yu et al. APASL consensus statements and management algorithms for hepatitis C infection Hepatol Int 6 2012 409 435
-
(2012)
Hepatol Int
, vol.6
, pp. 409-435
-
-
Omata, M.1
Kanda, T.2
Yu, M.-L.3
-
5
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
M.W. Fried, M.L. Shiffman, and K.R. Reddy et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
6
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
M.P. Manns, J.G. McHutchison, and S.C. Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
7
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
J.G. McHutchison, E.J. Lawitz, and M.L. Shiffman et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
-
8
-
-
33745214494
-
Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin
-
C. Berg, F.L. Goncales Jr., and D.E. Bernstein et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin J Viral Hepat 13 2006 435 440
-
(2006)
J Viral Hepat
, vol.13
, pp. 435-440
-
-
Berg, C.1
Goncales, Jr.F.L.2
Bernstein, D.E.3
-
9
-
-
70449408989
-
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
-
D.T. Dieterich, M. Rizzetto, and M.P. Manns Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin J Viral Hepat 16 2009 833 843
-
(2009)
J Viral Hepat
, vol.16
, pp. 833-843
-
-
Dieterich, D.T.1
Rizzetto, M.2
Manns, M.P.3
-
10
-
-
67349172961
-
Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
-
T. Poynard, M. Colombo, and J. Bruix et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
-
(2009)
Gastroenterology
, vol.136
, pp. 1618-1628
-
-
Poynard, T.1
Colombo, M.2
Bruix, J.3
-
11
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
B.R. Bacon, S.C. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
-
12
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
13
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, Jr.J.2
Bacon, B.R.3
-
14
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
-
15
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
K.E. Sherman, S.L. Flamm, and N.H. Afdhal et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
-
(2011)
N Engl J Med
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
-
16
-
-
33644636312
-
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
-
R.B. Perni, S.J. Almquist, and R.A. Byrn et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 2006 899 909
-
(2006)
Antimicrob Agents Chemother
, vol.50
, pp. 899-909
-
-
Perni, R.B.1
Almquist, S.J.2
Byrn, R.A.3
-
17
-
-
84901233284
-
-
Accessed February 3, 2014
-
RxList. Victrelis. Available at: http://www.rxlist.com/victrelis-drug/ clinical-pharmacology.htm. Accessed February 3, 2014.
-
RxList. Victrelis
-
-
-
18
-
-
84885871290
-
OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
-
M. Buti, K. Agarwal, and Y. Horsmans et al. OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients Hepatology 56 2012 191A 1144A
-
(2012)
Hepatology
, vol.56
-
-
Buti, M.1
Agarwal, K.2
Horsmans, Y.3
-
19
-
-
84864206329
-
Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C
-
X. Gao, J.M. Stephens, and J.A. Carter et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 2012 335 343
-
(2012)
Expert Rev Pharmacoecon Outcomes Res
, vol.12
, pp. 335-343
-
-
Gao, X.1
Stephens, J.M.2
Carter, J.A.3
-
20
-
-
84855244456
-
Boceprevir and telaprevir for the treatment of chronic hepatitis C: Safety management in clinical practice
-
C. Hezode Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice Liver Int 32 Suppl 1 2012 32 38
-
(2012)
Liver Int
, vol.32
, Issue.SUPPL. 1
, pp. 32-38
-
-
Hezode, C.1
-
21
-
-
84882908504
-
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890
-
C. Hezode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890 J Hepatol 59 2013 434 441
-
(2013)
J Hepatol
, vol.59
, pp. 434-441
-
-
Hezode, C.1
Fontaine, H.2
Dorival, C.3
-
22
-
-
84865454706
-
Safety of telaprevir for chronic hepatitis C virus infection: A meta-analysis of randomized controlled trials
-
H. Qin, H. Li, and X. Zhou et al. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials Clin Drug Investig 32 2012 665 672
-
(2012)
Clin Drug Investig
, vol.32
, pp. 665-672
-
-
Qin, H.1
Li, H.2
Zhou, X.3
-
26
-
-
84901188907
-
-
Janssen Products, LP Accessed January 22, 2014
-
TM - Highlights of prescribing information. Available at: http://www.olysio.com/shared/product/olysio/ prescribing-information.pdf. Accessed January 22, 2014.
-
TM - Highlights of Prescribing Information
-
-
-
27
-
-
84888295678
-
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study
-
M.W. Fried, M. Buti, and G.J. Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
-
(2013)
Hepatology
, vol.58
, pp. 1918-1929
-
-
Fried, M.W.1
Buti, M.2
Dore, G.J.3
-
28
-
-
84861188748
-
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
-
C. Moreno, T. Berg, and T. Tanwandee et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
-
(2012)
J Hepatol
, vol.56
, pp. 1247-1253
-
-
Moreno, C.1
Berg, T.2
Tanwandee, T.3
-
29
-
-
77449158033
-
Rapid HCV-RNA decline with once daily TMC435: A phase i study in healthy volunteers and hepatitis C patients
-
H.W. Reesink, G.C. Fanning, and K.A. Farha et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
-
(2010)
Gastroenterology
, vol.138
, pp. 913-921
-
-
Reesink, H.W.1
Fanning, G.C.2
Farha, K.A.3
-
30
-
-
84892806505
-
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
-
S. Zeuzem, T. Berg, and E. Gane et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2013 430 441.e6
-
(2013)
Gastroenterology
, vol.146
-
-
Zeuzem, S.1
Berg, T.2
Gane, E.3
-
31
-
-
84895736477
-
SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study
-
abstract LB-3
-
Jacobson IM, Ghalib R, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013;58:1379A, abstract LB-3.
-
(2013)
Hepatology
, vol.58
-
-
Jacobson, I.M.1
Ghalib, R.2
Rodriguez-Torres, M.3
-
32
-
-
80055076797
-
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: A randomized trial
-
M. Manns, H. Reesink, and T. Berg et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 2011 1021 1033
-
(2011)
Antivir Ther
, vol.16
, pp. 1021-1033
-
-
Manns, M.1
Reesink, H.2
Berg, T.3
-
33
-
-
84901233285
-
Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-2, a phase III trial
-
press
-
Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet, in press.
-
Lancet
-
-
Manns, M.1
Marcellin, P.2
Poordad, F.3
-
34
-
-
84901233286
-
Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-1, a phase III trial
-
press
-
Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Lancet, in press.
-
Lancet
-
-
Jacobson, I.1
Dore, G.J.2
Foster, G.R.3
-
35
-
-
0034533990
-
Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C
-
L. Kleinman, M.W. Zodet, and Z. Hakim et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C Qual Life Res 9 2000 499 508
-
(2000)
Qual Life Res
, vol.9
, pp. 499-508
-
-
Kleinman, L.1
Zodet, M.W.2
Hakim, Z.3
-
36
-
-
0027693577
-
The validity and reproducibility of a work productivity and activity impairment instrument
-
M.C. Reilly, A.S. Zbrozek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
-
(1993)
Pharmacoeconomics
, vol.4
, pp. 353-365
-
-
Reilly, M.C.1
Zbrozek, A.S.2
Dukes, E.M.3
-
37
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
J.G. McHutchison, M.P. Manns, and A.J. Muir et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
-
38
-
-
79951794050
-
Response-guided therapy for HCV
-
P.Y. Kwo Response-guided therapy for HCV Gastroenterol Hepatol (N Y) 7 2011 43 45
-
(2011)
Gastroenterol Hepatol (N Y)
, vol.7
, pp. 43-45
-
-
Kwo, P.Y.1
-
39
-
-
84901238396
-
Cost benefit analysis of response guided therapy: Dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages
-
abs 1167
-
P. McEwan, Y. Yuan, and G. Litauen et al. Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages J Hepatol 54 2011 S461 abs 1167
-
(2011)
J Hepatol
, vol.54
, pp. 461
-
-
McEwan, P.1
Yuan, Y.2
Litauen, G.3
-
40
-
-
84855219530
-
Response-guided and -unguided treatment of chronic hepatitis C
-
K.R. Reddy, F. Lin, and F. Zoulim Response-guided and -unguided treatment of chronic hepatitis C Liver Int 32 Suppl 1 2012 64 73
-
(2012)
Liver Int
, vol.32
, Issue.SUPPL. 1
, pp. 64-73
-
-
Reddy, K.R.1
Lin, F.2
Zoulim, F.3
-
42
-
-
33750369259
-
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
-
M. Sherman, E.M. Yoshida, and M. Deschenes et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy Gut 55 2006 1631 1638
-
(2006)
Gut
, vol.55
, pp. 1631-1638
-
-
Sherman, M.1
Yoshida, E.M.2
Deschenes, M.3
-
43
-
-
81855188786
-
In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters
-
abstract 278
-
Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010;52:461A, abstract 278.
-
(2010)
Hepatology
, vol.52
-
-
Huisman, M.T.1
Snoeys, J.2
Monbaliu, J.3
|